Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker

Pediatr Nephrol. 2005 Dec;20(12):1701-7. doi: 10.1007/s00467-005-1954-1. Epub 2005 Aug 5.

Abstract

Elevated plasma B-type natriuretic peptide (BNP) level is a hallmark of altered left ventricular (LV) structure and function. Measurement of circulating BNP has proved to be a sensitive and specific diagnostic test for congestive heart failure (CHF) and coronary syndrome in adults. Further, BNP levels constitute a strong predictive marker for future cardiovascular (CV) events. In high CV risk populations, such as adults with hypertension or chronic kidney disease (CKD), increased BNP predicts CV morbidity and mortality in symptomatic or asymptomatic patients. However, caution is needed in interpreting plasma BNP levels, as they increase with both age and decreased renal function. Despite increasing evidence of the value of BNP in the medical literature in adults, data in children are limited to those with congenital heart disease. It is appropriate to analyze the potential application of this tool in children with CKD, a well-known factor for CV disease.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Biomarkers / blood
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / mortality
  • Kidney Failure, Chronic / physiopathology*
  • Male
  • Models, Biological
  • Natriuretic Peptide, Brain / blood*
  • Predictive Value of Tests
  • Risk Assessment / methods*
  • Risk Factors
  • Ventricular Function, Left*

Substances

  • Biomarkers
  • Natriuretic Peptide, Brain